[SCHEDULE 13G] Lexeo Therapeutics, Inc. SEC Filing
Balyasny Asset Management and related entities reported beneficial ownership of 8,345,651 shares of Lexeo Therapeutics common stock, representing approximately 9.99% of the outstanding shares based on the issuer's reported share count. The position includes 4,336,514 shares issuable upon exercise of warrants, and the filing states the warrants cannot be exercised to the extent they would cause the holders to beneficially own more than 9.99% (a 9.99% blocker).
The filing explains that the reported shares are held through an investment client (Atlas Diversified Master Fund, Ltd.) for which Balyasny serves as investment manager, and that the Reporting Persons have sole voting and dispositive power over the reported shares. The Reporting Persons certified the holdings were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control.
Balyasny Asset Management e entit脿 correlate hanno dichiarato la titolarit脿 effettiva di 8.345.651 azioni ordinarie di Lexeo Therapeutics, pari a circa il 9,99% del capitale sociale in circolazione secondo il numero di azioni comunicato dall'emittente. La posizione comprende 4.336.514 azioni esercitabili mediante l'esercizio di warrant, e la comunicazione precisa che i warrant non possono essere esercitati nella misura in cui ci貌 porterebbe i detentori a possedere beneficiariamente pi霉 del 9,99% (clausola di blocco al 9,99%).
La comunicazione spiega che le azioni dichiarate sono detenute tramite un cliente d'investimento (Atlas Diversified Master Fund, Ltd.) per il quale Balyasny svolge il ruolo di gestore degli investimenti, e che le persone che riportano l'informazione detengono l'esclusivo potere di voto e di disposizione sulle azioni indicate. Le persone segnalanti hanno certificato che le partecipazioni sono state acquisite e sono detenute nell'ordinario svolgimento dell'attivit脿 e non allo scopo di modificare o influenzare il controllo.
Balyasny Asset Management y entidades relacionadas informaron la titularidad beneficiaria de 8.345.651 acciones ordinarias de Lexeo Therapeutics, que representan aproximadamente el 9,99% de las acciones en circulaci贸n seg煤n el n煤mero de acciones informado por el emisor. La posici贸n incluye 4.336.514 acciones que pueden emitirse al ejercer warrants, y la presentaci贸n indica que los warrants no pueden ejercerse en la medida en que hicieran que los titulares posean beneficiariamente m谩s del 9,99% (un bloqueador del 9,99%).
La presentaci贸n explica que las acciones declaradas se mantienen a trav茅s de un cliente de inversi贸n (Atlas Diversified Master Fund, Ltd.) para el cual Balyasny act煤a como gestor de inversiones, y que las personas informantes tienen el poder exclusivo de voto y disposici贸n sobre las acciones informadas. Las personas informantes certificaron que las participaciones se adquirieron y se mantienen en el curso ordinario del negocio y no con el prop贸sito de cambiar o influir en el control.
Balyasny Asset Management 氚� 甏�霠� 氩曥澑霌れ潃 Lexeo Therapeutics 氤错喌欤� 8,345,651欤茧ゼ 鞁れ唽鞙�(beneficial ownership)頃橁碃 鞛堧嫟瓿� 氤搓碃頄堨溂氅�, 鞚措姅 氚滍枆靷皜 氤搓碃頃� 欤检嫕 靾橂ゼ 旮办鞙茧 鞎� 9.99%鞐� 頃措嫻頃╇媹雼�. 頃措嫻 氤挫湢鞐愲姅 鞗岆煱韸� 頄夓偓搿� 歆�旮� 臧�電ロ暅 4,336,514欤缄皜 韽暔霅橂┌, 鞝滌稖靹滊鞐愲姅 鞗岆煱韸戈皜 氤挫湢鞛愱皜 鞁れ鞝侅溂搿� 靻岇湢頃橂姅 歆�攵勳澊 9.99%毳� 齑堦臣頃橃 鞎婋弰搿� 頃橂姅(9.99% 彀嫧) 瓴届毎鞐愲姅 頄夓偓霅� 靾� 鞐嗠嫟瓿� 氇呾嫓霅橃柎 鞛堨姷雼堧嫟.
靹滊電� 氤搓碃霅� 欤检嫕鞚� Balyasny臧� 韴瀽 毵る媹鞝�搿滌劀 甏�毽晿電� 韴瀽韥措澕鞚挫柛韸�(Atlas Diversified Master Fund, Ltd.)毳� 韱淀暣 氤挫湢霅橁碃 鞛堨溂氅�, 氤搓碃鞚鸽摛鞚� 頃措嫻 欤检嫕鞐� 雽�頃� 雼弲 鞚橁舶甓� 氚� 觳橂秳甓岇潉 氤挫湢頃橁碃 鞛堧嫟瓿� 靹る獏頃╇媹雼�. 氤搓碃鞚鸽摛鞚� 鞚� 歆�攵勳澊 鞓侅梾頇滊彊鞚� 韱奠儊鞝侅澑 氩旍渼鞐愳劀 旆摑路氤挫湢霅� 瓴冹澊氅� 歆�氚瓣秾 氤�瓴届澊雮� 鞓來枼霠レ潉 頄夓偓頃� 氇╈爜鞚� 鞎勲嫎鞚� 歃濍獏頄堨姷雼堧嫟.
Balyasny Asset Management et des entit茅s affili茅es ont d茅clar茅 la propri茅t茅 b茅n茅ficiaire de 8 345 651 actions ordinaires de Lexeo Therapeutics, repr茅sentant environ 9,99% des actions en circulation selon le nombre d'actions communiqu茅 par l'茅metteur. La position comprend 4 336 514 actions susceptibles d'锚tre 茅mises 脿 l'exercice de warrants, et le d茅p么t indique que les warrants ne peuvent pas 锚tre exerc茅s dans la mesure o霉 cela am猫nerait les titulaires 脿 d茅tenir b茅n茅ficiairement plus de 9,99% (clause de blocage 脿 9,99%).
Le d茅p么t pr茅cise que les actions d茅clar茅es sont d茅tenues par l'interm茅diaire d'un client d'investissement (Atlas Diversified Master Fund, Ltd.) pour lequel Balyasny agit en tant que gestionnaire d'investissement, et que les personnes rapportant l'information disposent du seul pouvoir de vote et de disposition sur les actions d茅clar茅es. Les d茅clarants ont certifi茅 que les participations ont 茅t茅 acquises et sont d茅tenues dans le cours normal des affaires et non dans le but de modifier ou d'influencer le contr么le.
Balyasny Asset Management und verbundene Unternehmen meldeten eine wirtschaftliche Eigent眉merschaft an 8.345.651 Aktien der Stammaktien von Lexeo Therapeutics, was gem盲脽 der vom Emittenten gemeldeten Aktienanzahl etwa 9,99% der ausstehenden Aktien entspricht. Die Position umfasst 4.336.514 Aktien, die bei Aus眉bung von Warrants ausgegeben werden k枚nnen, und die Meldung stellt klar, dass die Warrants nicht ausge眉bt werden d眉rfen, soweit dadurch die Inhaber wirtschaftlich mehr als 9,99% besitzen w眉rden (eine 9,99%-Sperrklausel).
In der Meldung wird erkl盲rt, dass die angegebenen Aktien 眉ber einen Investmentkunden (Atlas Diversified Master Fund, Ltd.) gehalten werden, f眉r den Balyasny als Investmentmanager fungiert, und dass die meldenden Personen alleinige Stimm- und Verf眉gungsgewalt 眉ber die angegebenen Aktien haben. Die meldenden Personen haben bescheinigt, dass die Best盲nde im normalen Gesch盲ftsverlauf erworben und gehalten werden und nicht zum Zweck einer 脛nderung oder Beeinflussung der Kontrolle dienen.
- 8,345,651 shares beneficially owned reported, representing 9.99% of the company's outstanding common stock
- Position explicitly includes 4,336,514 shares issuable upon exercise of warrants, providing potential additional economic interest subject to limits
- Reporting Persons certified holdings were acquired and are held in the ordinary course of business and not for control
- Warrants are subject to a 9.99% blocker, preventing exercise to the extent they would increase beneficial ownership above 9.99%
- The reported shares are held through an investment client (ADMF), meaning the Reporting Persons' economic interest is on behalf of another person rather than direct ownership
Insights
TL;DR: Balyasny discloses a near-10% beneficial stake in Lexeo, including exercisable warrants constrained by a 9.99% blocker.
The Schedule 13G shows an aggregate position of 8,345,651 shares, equal to ~9.99% of the issuer's reported outstanding common stock (33,196,997 shares). That total explicitly includes 4,336,514 shares issuable upon exercise of warrants but notes those warrants cannot be exercised beyond the 9.99% ownership cap. The filing also identifies the direct holder as an investment client (ADMF) for which the Reporting Persons act as investment manager, and the Reporting Persons assert the holdings are held in the ordinary course and not for control purposes. For investors, this is a material disclosure of substantial passive interest without an asserted intent to change control.
TL;DR: A near-10% passive disclosure with voting and dispositive power reported, constrained by warrant exercise limits and disclosed client ownership.
The filing documents that each Reporting Person may be deemed to exercise voting and investment power over the reported shares by virtue of their managerial relationships, and lists sole voting and dispositive power for 8,345,651 shares. It also clarifies the economic holder is an investment client (ADMF), which has the right to dividends and sale proceeds. The Schedule 13G format and the certification in the filing indicate the Reporting Persons assert a passive holding rather than an intent to influence control.
Balyasny Asset Management e entit脿 correlate hanno dichiarato la titolarit脿 effettiva di 8.345.651 azioni ordinarie di Lexeo Therapeutics, pari a circa il 9,99% del capitale sociale in circolazione secondo il numero di azioni comunicato dall'emittente. La posizione comprende 4.336.514 azioni esercitabili mediante l'esercizio di warrant, e la comunicazione precisa che i warrant non possono essere esercitati nella misura in cui ci貌 porterebbe i detentori a possedere beneficiariamente pi霉 del 9,99% (clausola di blocco al 9,99%).
La comunicazione spiega che le azioni dichiarate sono detenute tramite un cliente d'investimento (Atlas Diversified Master Fund, Ltd.) per il quale Balyasny svolge il ruolo di gestore degli investimenti, e che le persone che riportano l'informazione detengono l'esclusivo potere di voto e di disposizione sulle azioni indicate. Le persone segnalanti hanno certificato che le partecipazioni sono state acquisite e sono detenute nell'ordinario svolgimento dell'attivit脿 e non allo scopo di modificare o influenzare il controllo.
Balyasny Asset Management y entidades relacionadas informaron la titularidad beneficiaria de 8.345.651 acciones ordinarias de Lexeo Therapeutics, que representan aproximadamente el 9,99% de las acciones en circulaci贸n seg煤n el n煤mero de acciones informado por el emisor. La posici贸n incluye 4.336.514 acciones que pueden emitirse al ejercer warrants, y la presentaci贸n indica que los warrants no pueden ejercerse en la medida en que hicieran que los titulares posean beneficiariamente m谩s del 9,99% (un bloqueador del 9,99%).
La presentaci贸n explica que las acciones declaradas se mantienen a trav茅s de un cliente de inversi贸n (Atlas Diversified Master Fund, Ltd.) para el cual Balyasny act煤a como gestor de inversiones, y que las personas informantes tienen el poder exclusivo de voto y disposici贸n sobre las acciones informadas. Las personas informantes certificaron que las participaciones se adquirieron y se mantienen en el curso ordinario del negocio y no con el prop贸sito de cambiar o influir en el control.
Balyasny Asset Management 氚� 甏�霠� 氩曥澑霌れ潃 Lexeo Therapeutics 氤错喌欤� 8,345,651欤茧ゼ 鞁れ唽鞙�(beneficial ownership)頃橁碃 鞛堧嫟瓿� 氤搓碃頄堨溂氅�, 鞚措姅 氚滍枆靷皜 氤搓碃頃� 欤检嫕 靾橂ゼ 旮办鞙茧 鞎� 9.99%鞐� 頃措嫻頃╇媹雼�. 頃措嫻 氤挫湢鞐愲姅 鞗岆煱韸� 頄夓偓搿� 歆�旮� 臧�電ロ暅 4,336,514欤缄皜 韽暔霅橂┌, 鞝滌稖靹滊鞐愲姅 鞗岆煱韸戈皜 氤挫湢鞛愱皜 鞁れ鞝侅溂搿� 靻岇湢頃橂姅 歆�攵勳澊 9.99%毳� 齑堦臣頃橃 鞎婋弰搿� 頃橂姅(9.99% 彀嫧) 瓴届毎鞐愲姅 頄夓偓霅� 靾� 鞐嗠嫟瓿� 氇呾嫓霅橃柎 鞛堨姷雼堧嫟.
靹滊電� 氤搓碃霅� 欤检嫕鞚� Balyasny臧� 韴瀽 毵る媹鞝�搿滌劀 甏�毽晿電� 韴瀽韥措澕鞚挫柛韸�(Atlas Diversified Master Fund, Ltd.)毳� 韱淀暣 氤挫湢霅橁碃 鞛堨溂氅�, 氤搓碃鞚鸽摛鞚� 頃措嫻 欤检嫕鞐� 雽�頃� 雼弲 鞚橁舶甓� 氚� 觳橂秳甓岇潉 氤挫湢頃橁碃 鞛堧嫟瓿� 靹る獏頃╇媹雼�. 氤搓碃鞚鸽摛鞚� 鞚� 歆�攵勳澊 鞓侅梾頇滊彊鞚� 韱奠儊鞝侅澑 氩旍渼鞐愳劀 旆摑路氤挫湢霅� 瓴冹澊氅� 歆�氚瓣秾 氤�瓴届澊雮� 鞓來枼霠レ潉 頄夓偓頃� 氇╈爜鞚� 鞎勲嫎鞚� 歃濍獏頄堨姷雼堧嫟.
Balyasny Asset Management et des entit茅s affili茅es ont d茅clar茅 la propri茅t茅 b茅n茅ficiaire de 8 345 651 actions ordinaires de Lexeo Therapeutics, repr茅sentant environ 9,99% des actions en circulation selon le nombre d'actions communiqu茅 par l'茅metteur. La position comprend 4 336 514 actions susceptibles d'锚tre 茅mises 脿 l'exercice de warrants, et le d茅p么t indique que les warrants ne peuvent pas 锚tre exerc茅s dans la mesure o霉 cela am猫nerait les titulaires 脿 d茅tenir b茅n茅ficiairement plus de 9,99% (clause de blocage 脿 9,99%).
Le d茅p么t pr茅cise que les actions d茅clar茅es sont d茅tenues par l'interm茅diaire d'un client d'investissement (Atlas Diversified Master Fund, Ltd.) pour lequel Balyasny agit en tant que gestionnaire d'investissement, et que les personnes rapportant l'information disposent du seul pouvoir de vote et de disposition sur les actions d茅clar茅es. Les d茅clarants ont certifi茅 que les participations ont 茅t茅 acquises et sont d茅tenues dans le cours normal des affaires et non dans le but de modifier ou d'influencer le contr么le.
Balyasny Asset Management und verbundene Unternehmen meldeten eine wirtschaftliche Eigent眉merschaft an 8.345.651 Aktien der Stammaktien von Lexeo Therapeutics, was gem盲脽 der vom Emittenten gemeldeten Aktienanzahl etwa 9,99% der ausstehenden Aktien entspricht. Die Position umfasst 4.336.514 Aktien, die bei Aus眉bung von Warrants ausgegeben werden k枚nnen, und die Meldung stellt klar, dass die Warrants nicht ausge眉bt werden d眉rfen, soweit dadurch die Inhaber wirtschaftlich mehr als 9,99% besitzen w眉rden (eine 9,99%-Sperrklausel).
In der Meldung wird erkl盲rt, dass die angegebenen Aktien 眉ber einen Investmentkunden (Atlas Diversified Master Fund, Ltd.) gehalten werden, f眉r den Balyasny als Investmentmanager fungiert, und dass die meldenden Personen alleinige Stimm- und Verf眉gungsgewalt 眉ber die angegebenen Aktien haben. Die meldenden Personen haben bescheinigt, dass die Best盲nde im normalen Gesch盲ftsverlauf erworben und gehalten werden und nicht zum Zweck einer 脛nderung oder Beeinflussung der Kontrolle dienen.
FAQ
How many LXEO shares does Balyasny beneficially own?
What percent of LXEO does the Balyasny position represent?
Does the Balyasny position include warrants for LXEO?
Who is the direct holder of the reported LXEO shares?
Did the Reporting Persons state intent to influence control of LXEO?
